Total votes: 0

Sirtex is a profitable biotech generating real cashflow and founded in 1997. It has developed a treatment for liver cancer, which is the fifth most widespread cancer. In July 2011 the company reported that sales of its SIR-Spheres® microspheres, it’s targeted radioactive treatment for inoperable liver cancer, grew 23% in the fourth quarter of the 2011 Financial Year compared with the same quarter last year. Full year dose sales grew 19.3% compared to a 14% growth the year before.

Patients are injected with a small particle in a process called selective internal radiation therapy. The particles are less than the width of a human hair and are injected into the hepatic artery, lodging themselves in the tumour and delivering concise high doses of radiation.

An international trend of sales has begun with a move into Asia and ongoing penetration in the biggest markets i.e. US and Europe.

Cash on hand: In February 2011 the comapny reported cash on hand of $41.2 million.

Revenue increased by 72 per cent in teh last annual period to $65.6 million.

The comapny granted a dividend of 7 cents (fully franked) per share on the 14th of October 2010.